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Abstract Apoptotic protease-activating factor 1 (APAF-1) is
a central component of the intrinsic pathway of apoptosis. Our
study aims at searching the role of APAF-1 in iron overload
myelodysplastic syndrome (MDS). Erythroid apoptosis rate,
mRNA expression levels of APAF-1, and caspase-9 activity
were determined by flow cytometry, quantitative real-time
PCR, and colorimetric assay in MDS patients, respectively.
In addition, K562 and MDS-L cell lines were incubated with
different concentrations of ferric ammonium citrate (FAC) or
ferric ammonium citrate+desferrioxamine (FAC+DFO)
in vitro to observe the alteration in erythrocyte apoptosis
rate, APAF-1 mRNA, and protein expression levels. More-
over, as control, erythroid apoptosis rate and APAF-1
mRNA expression were detected after silencing APAF-1
expression by endoribonuclease-prepared small interfering
RNAs (esiRNAs) in K562 and MDS-L cell lines. Both
erythroid apoptosis rate and APAF-1 mRNA expression of
the iron overload (IO) group were significantly higher than
those of the non-IO group (P <0.001 and P <0.001). There
is a significant difference of caspase-9 activity between the
IO group and the non-IO group (P <0.001). Erythroid
apoptosis rate and APAF-1 mRNA expression of K562 and
MDS-L cell lines significantly elevated after FAC incubation
in different concentrations (P <0.001 and P <0.001 for K562;
P <0.001 and P <0.001 for MDS-L), while erythroid apopto-
sis rate and APAF-1 mRNA expression in the FAC+DFO
group declined (P <0.001 and P <0.001 for K562; P <0.001
and P <0.001 for MDS-L). After silencing of APAF-1 expres-
sion with specific esiRNAs, erythroid apoptosis rate and
APAF-1 mRNA expression of K562 and MDS-L cell lines
markedly decreased (P <0.001 and P <0.001 for K562;
P <0.001 and P <0.001 for MDS-L). APAF-1 plays an
important role in iron-induced erythroid apoptosis increase
in MDS.
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Introduction
Myelodysplastic syndromes (MDSs) comprise a heteroge-
neous group of hematopoietic stem cell malignancies charac-
terized by peripheral cytopenias and have a substantial risk of
progression to acute myeloid leukemia (AML) [1]. The most
common form of cytopenia in MDS is anemia [2]. It is
believed that the main cause of iron overload in MDS is
repeated blood transfusion [3] and most of the patients who
present with anemia become transfusion dependent during the
clinical course of the disease [4].
In the human body, circulating iron is bound to transferrin.
When the binding capacity of transferrin is exceeded, non-
transferrin-bound iron (NTBI) species appear in the plasma
[5]. NTBI contributes to the generation of reactive oxygen
species (ROS). ROS-induced damage may enhance the apo-
ptotic activity of MDS-derived hematopoietic precursors and
induce mitochondrial defects and cytochrome C release, thus
triggering apoptosis [6]. The mitochondria-dependent apopto-
tic pathway is involved in the mechanism of erythroid apo-
ptosis in MDS. The apoptosome, which includes the protein
apoptotic protease-activating factor 1 (APAF-1), cytochrome
c/dATP, and procaspase-9, plays a central role in the apoptotic
process. Triggering the death receptors or direct damage to
mitochondria results in cytochrome C release and caspase-9
downstream activation via APAF-1-mediated apoptosome
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formation [7, 8]. Cytochrome C is released frommitochondria
into the cytosol after the induction of apoptosis by many
different stimuli. The released cytochrome C associates with
APAF-1 in the presence of dATP or ATP and induces the
oligomerization of APAF-1. This recognizes inactive
procaspase-9 and forms the apoptosome, triggering autocata-
lytic processing of procaspase-9. Activated caspase-9 then
processes effector caspases (caspase-3, caspase-6, and
caspase-7), which in turn cause cell collapse by cleaving a
specific set of substrates.
In order to study the role of APAF-1 in iron overload
MDS, APAF-1 mRNA expression and erythroid apoptosis
were detected in MDS patients and an iron overload
model was established by using ferric ammonium citrate
(FAC) in K562 and MDS-L cell lines. APAF-1 mRNA
and protein expression and erythroid apoptosis rate were
determined before and after FAC incubation. Moreover,
deferoxamine (DFO), as control, was used to reduce the
load of iron to observe the change of APAF-1 mRNA
expression and erythroid apoptosis rate under iron chela-
tion therapy. Finally, we used K562 and MDS-L cell lines




Patients diagnosed with MDS between 2010 and 2012 at the
Department of Hematology in the Sixth People's Hospital
affiliated to Shanghai Jiaotong University (Shanghai, China)
were enrolled in this study. Thirty-fiveMDS patients (de novo
or only treated with transfusion) were included. Written in-
formed consent in accordancewith the Declaration of Helsinki
was obtained from the patients or the next of kin, caretakers,
or guardians on behalf of the children participants prior to the
study. Table 1 shows patients' main characteristics. Patients
were categorized according to the 2008 version of the World
Health Organization (WHO) Classification of MDS [9]. Two
grouping strategies for prognostic stratification were
adopted and carried out separately. The first strategy was
based on the International Prognostic Scoring System
(IPSS) [10], which defined low risk and intermediate-1
as IPSS lower-risk group and intermediate-2 and high risk
as IPSS higher-risk group. The second strategy followed
the Revised IPSS (IPSS-R) [11], which defined very low
risk and low risk as IPSS-R lower-risk group and the
other three risk groups (intermediate-1, intermediate-2,
and high risk) as IPSS-R higher-risk group. The iron
overload (IO) group involved 18 patients with adjusted
serum ferritin (ASF) more than 1,000 ng/mL, while the
non-iron overload (non-IO) group involved the remaining
17 patients [3]. APAF-1 mRNA expression in seven
healthy volunteers served as a calibrator for MDS patients.
The study was approved by the Ethics Committee of the
Sixth People's Hospital affiliated to Shanghai Jiaotong
University.
Cell culture and in vitro iron overload model
The K562 cell line obtained from American Type Culture
Collection (ATCC) (Rockville, MD, USA) was cultured in
RPMI-1640 medium supplemented with fetal bovine serum
(FBS) and penicillin–streptomycin (PS). The MDS-L cell line
gifted by Dr. Kaoru Tohyama from Kawasaki Medical School
(Okayama, Japan) was cultured in RPMI-1640 medium sup-
plemented with FBS, PS, interleukin-3 (IL-3), HEPES buffer,
L-glutamine, and 2-mercaptoethanol. MDS-L was derived as
a subline from a myelodysplastic cell line. MDS-L cells were
positive for CD34, c-Kit, HLA-DR, CD13, and CD33, par-
tially positive for CD41, and negative for CD3, CD14, CD20,
and CD235a. The characteristics of MDS-L have previously
been described in detail [13]. Although the MDS-L cell line is
reported negative for CD235a, our preliminary experiment
demonstrated a weaken expression of CD235a by flow cy-
tometry. While MDS-L is the only cell line derived from
MDS, we detected its APAF-1 expression and erythroid apo-
ptosis assays as well.
Cells were seeded at 106 cells/mL in six-well plates and
maintained at 37 °C under 5 % CO2. FAC (Sigma-Aldrich,
USA) was used to set up an in vitro iron overload model. Both
K562 and MDS-L cell lines were incubated with different
concentrations of FAC (0, 1, 2, 4, and 8 μmol/L) for up to
24 h. To control for the specificity of the effect of iron,
10μmol/L of DFO (Novartis Pharma, Switzerland) was added
to half of the wells. After incubation, the cells were washed
twice with phosphate-buffered solution (PBS) for magnetic
separation of CD235a+ cells and erythroid apoptosis assay. All
the experiments were repeated five times.
esiRNAs mediated silencing of cell lines
Endoribonuclease-prepared small interfering RNAs
(esiRNAs; Sigma-Aldrich, USA), which target APAF-1
mRNAs, were transiently transfected into K562 and MDS-L
cell lines using a TransLipid Transfection Reagent (TransGen
Biotech, China). Briefly, every 1×106 cells were resuspended
in 1 mL of RPMI-1640 antibiotic-free medium and seeded in
six-well plates. The esiRNA–TransLipid compound was pre-
pared following the manufacturer's protocol. Then, the cells
were incubated with 300 μL of esiRNA–TransLipid com-
pound at 37 °C under 5 % CO2. After 48 h of transfection,
the cells were harvested. The effect of esiRNA nucleofection
on specific mRNA levels was quantified by quantitative real-
time polymerase chain reaction (qRT-PCR).
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Serum ferritin and C-reactive protein assays
Serum ferritin (SF) was detected to assess iron overload of
MDS patients using standard commercial assays at the clinical
laboratory of Shanghai Sixth People's Hospital. Considering
that inflammation may affect the result of SF, C-reactive
protein (CRP) was measured along with SF. They are both
acute-phase reactants. CRP served as adjustment for SF. ASF
was adopted when CRP was higher than 10.0 mg/L. ASF is
defined as SF (mg/L) divided by the log10 of CRP (mg/L). If
CRP was equal to or less than 10.0 mg/L, the ASF was simply
the SF [12].
Magnetic separation of CD235a+ cells
Bone marrow mononuclear cells (BMMNCs) were isolated
from 7 mL of bone marrow samples with heparin sodium as
the anticoagulant: 5 mL for positive selection of CD235a cells
and 2 mL for flow cytometry assays. CD235a+ mature eryth-
rocytes and erythroid precursor cells were separated from
BMMNCs with magnetic microbeads (Miltenyi Biotec,
Germany), according to the manufacturer's protocol.
Flow cytometry for erythroid apoptosis assay
For erythroid apoptosis assay, a cell solution at 106/mL was
prepared by adding PBS. A total 100 μL of the cell suspension
was incubated with PE-conjugated anti-CD235a monoclonal
antibody at room temperature away from light for 15 min.
After incubation, the cells were washed once with PBS. Then,
the cells were incubated with 5 μL of FITC-conjugated
annexin V for 10 min. Additional staining with 5 μL of
7AAD was performed to discriminate dead and live cells.
The cells were analyzed by flow cytometry within half an
hour on a FACS Calibur (Becton-Dickinson, USA). All anti-
bodies were purchased from Invitrogen (Invitrogen, USA).
qRT-PCR assay
The RNA extracted from CD235a+ cells using RNeazy Mini
Kit (QIAGEN, Germany) served as the template for all reverse
transcriptase reactions. Synthesized cDNAwas obtained from
10 μL of RNA via random priming, with the aid of
RevertAidTM First Strand cDNA Synthesis Kit (Fermentas,
Canada) following the manufacturer's protocol. The PCR
totals 20 μL in volume and includes the following: 2 μL of
cDNA solution mixed with 10 μL of SYBR® Premix Ex
TaqTMII (TaKaRa, Japan), 0.4 μL for each of forward primers
and reverse primers, and 7.2 μL of RNase-free water. A
fluorescent quantitation PCR cycler (LightCycler, Roche,
Switzerland) was used for amplification of APAF-1 and
GAPDH with the following primer pairs: APAF-1 forward
(for), GTCTGCTGATGGTGCAAGGA; APAF-1 reverse
(rev), GATGGCCCGTGTGGATTTC; GDF15 forward (for),
GTGTTGCTGGTGCTCTCGTG; GDF15 reverse (rev),
CGGTGTTCGAATCTTCCCAG; GAPDH forward (for),
GCACCGTCAAGGCTGAGAAC; GAPDH reverse (rev),
GTGGTGAAGACGCCAGTGGA. The amplification proce-
dure consisted of three steps: (1) denaturation at 95 °C for 5 s,
(2) annealing at 62 °C for 20 s, and (3) extension at 72 °C for
10 s (43 cycles). The threshold cycle (Ct) was subsequently
determined. Expression levels of APAF-1 and GDF15 nor-
malized to GAPDH and relative to a calibrator was expressed
as 2−ΔΔCt (fold difference). Here, GDF15 was measured for
predicting ineffective or apoptotic erythropoiesis. Details will
be described in the part of “Discussion”.
Table 1 The main characteristics
of MDS patients Parameters IO group (n =18) Non-IO group (n=17) P value
Median age, years (range) 58 (29–83) 61 (15–80) 0.482
Sex, male/female 9/9 10/7 0.738
Diagnosis by WHO 2008 classification (%)
RCUD/RARS/5q−syndrome/RCMD 72 53 0.305
RAEB-1/RAEB-2 28 47
IPSS score (%)
Low/Int-1 risk 94 35 <0.001
Int-2/high risk 6 65
IPSS-R score (%)
Very low/low risk 7 2 0.121
Int/high/very high risk 11 15
Median months on transfusion therapy (range) 14.5 (7–28) 4 (0–11) <0.001
Median red blood cell units transfused (range) 39.5 (17–86) 9 (0–31) <0.001
ASF (mg/L) 2,518.2±1,908.8 452.1±224.6 <0.001
APAF-1 mRNA expression (2−ΔΔCt) 7.05±3.19 1.95±1.23 <0.001
Erythroid apoptosis rate (%) 36.08±10.20 19.32±6.39 <0.001
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Western blot assay
To obtain CD235a+ cell lysates from the K562 cell line, cells
were lysed on ice for 20 min in a mammalian protein extrac-
tion reagent (CWBIO, China). Cell lysates were then centri-
fuged, and supernatants were collected. Protein concentration
was measured using the BCA Protein Assay Kit (CWBIO,
China). TheWestern blot procedure was as follows: (1) 16 μL
of each protein sample was loaded onto a SDS gel for elec-
trophoresis; (2) the proteins were transferred onto nitrocellu-
lose membranes; (3) the proteins were blocked in 5 % milk
and labeled with antibodies against APAF-1 (Abcam, USA),
GAPDH (HuaAn Biotech, China), and relevant secondary
antibodies (Abcam, USA); and (4) the proteins were visual-
ized by enhanced chemiluminescence (Bio-Rad, USA). The
films were scanned using the Epson Perfection 4490 Scanner
(EPSON Europe B.V., Sweden).
Colorimetric assay
Caspase-9 is in the process of cell apoptosis signal
transduction pathway. Combined with the cytochrome
C released from mitochondria and APAF-1, caspase-9
can form a compound which is so-called apoptosome
and activate at the same time. Activation of the key
enzymes of caspase-9 can activate caspase-3, thereby
promoting apoptosis signal. We used a colorimetric assay kit
(Bio-Box, China) to determine caspase-9 activity of MDS
patients according to the manufacturer's protocol. One unit is
the amount of enzyme that will cleave 1.0 nmol of the color-
imetric substrate Ac-LEHD-pNA per hour at 37 °C under
saturated substrate concentrations.
Statistical analysis
The statistical analysis was performed using the SPSS 17.0
software (SPSS Inc., Chicago, IL, USA). Quantitative data
were expressed as means±SD and tested using Student's t test
or analysis of variance (ANOVA). A paired sample t test was
used for the analysis between FAC and FAC+DFO, and FAC
and FAC+esiRNAs. Pearson's correlation analysis was per-
formed between GDF15 and APAF-1 mRNA expression.
P <0.05 was considered as statistical significant.
Results
APAF-1 mRNA expression, caspase-9 activity, and erythroid
apoptosis rate in MDS
SF still remains an essential monitoring parameter for iron
overload. However, confounding factors such as iron storage,
inflammation, tumor, and transfusion have to be taken into
account. Therefore, we introduced ASF adjusted by CRP into
our study to eliminate the influence of inflammation on SF.
Figure 1 shows that APAF-1 mRNA expression of the
IO group is 7.05±3.19 while that of the non-IO group is
1.95±1.23. APAF-1 mRNA expression in the IO group was
significantly higher than that in the non-IO group (P <0.001).
There was no statistical difference in APAF-1 expression
between the IPSS lower-risk group and the IPSS higher-
risk group in IO patients and non-IO patients, respectively
(P=0.695 and P=0.317); APAF-1 mRNA expression in
the lower-risk group was higher than that in the higher-
risk group (P=0.004). No significant difference was found
between the IPSS-R lower-risk group and the IPSS-R
higher-risk group (P=0.170). GDF15 mRNA expression
levels had a statistical correlation with APAF-1 mRNA
expression level in the non-IO group (r =0.542, P=0.025),
but there was no association between GDF15 and APAF-1
in the IO group (r =0.170, P=0.499). Caspase-9 activity
was used to further demonstrate the role of APAF-1 in
MDS. As Fig. 2 shows, there is a significant difference of
Fig. 1 APAF-1 mRNA expression of CD235a+ erythroid cells in MDS
patients. The APAF-1 mRNA expression of the iron overload (IO)
group is 7.05±3.19. The APAF-1 mRNA expression of the non-iron
overload (nIO) group is 1.95±1.23. There is a statistical significance
of APAF-1 mRNA expression between the IO group and the non-IO
group (P<0.001)
Fig. 2 The caspase-9 activity of MDS patients. Caspase-9 activity was
used to further demonstrate the role of APAF-1 in MDS. There is a
significant difference of caspase-9 activity between the IO group and
the non-IO group (P <0.001)
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caspase-9 activity between the IO group and the non-IO
group (P <0.001).
The erythroid apoptosis rate of the IO group is 36.08±
10.20%,while that of the non-IO group is 19.32±6.39%. The
IO group had a higher erythroid apoptosis rate than the non-IO
group (P <0.001) (Fig. 3).
Cell lines in iron overload model
Figure 4 shows one of the results of erythroid apoptosis assay
of K562 and MDS-L cell lines after incubation with different
concentrations of FAC (P <0.001 and P <0.001). The ery-
throid apoptosis rate increased along with increasing FAC
concentration.
Figure 5 demonstrates APAF-1 protein expression of the
K562 cell line after incubation with different concentrations of
FAC. With the increase of FAC concentration, APAF-1 pro-
tein expression presented a rising trend.
Erythroid apoptosis rate in K562 and MDS-L cell lines
decreased after FAC+DFO incubation and silencing
of APAF-1
After incubation with esiRNAs, APAF-1 mRNA expression
is 88.56±1.49 % knockdown in the K562 cell line while
90.27±0.39 % knockdown in the MDS-L cell line. Figure 5
shows the change in erythroid apoptosis rate before and
after silencing of APAF-1 in K562 and MDS-L cell lines.
Incubation with FAC+DFO induced a significant decline in
apoptosis rate and mRNA expression in K562 (P <0.001
and P <0.001) and MDS-L (P <0.001 and P <0.001) cell
lines. After silencing of APAF-1 expression with specific
esiRNAs, the apoptosis rate and mRNA expression dropped
markedly in K562 (P <0.001 and P <0.001) and MDS-L
(P <0.001 and P <0.001) cell lines as well (Fig. 6).
Discussion
Many MDS patients become dependent on blood transfusions
and develop transfusional iron overload, which is exacerbated
by increased absorption of dietary iron in response to ineffec-
tive erythropoiesis [3]. The erythroid apoptosis of MDS, par-
ticularly sideroblastic anemia, is mediated by mitochondrial
Fig. 3 The erythroid apoptosis rate of MDS patients. The erythroid
apoptosis rate of the iron overload (IO) group is 36.08±10.20 %.
The erythroid apoptosis rate of the non-iron overload (nIO) group is
19.32±6.39 %. IO group patients have a higher erythroid apoptosis
rate than non-IO group patients (P<0.001)
Fig. 4 The erythroid apoptosis rate of K562 and MDS-L cell lines after
incubation of FAC in different concentrations. The figure shows one of
the results of erythroid apoptosis assay of K562 and MDS-L cell lines
after incubation of FAC in different concentrations (from left to right:
blank, 1 μmol/L, 2 μmol/L, 4 μmol/L, 8 μmol/L). Erythroid apoptosis
rate was elevating along with the increase of FAC concentration. The
P value is 0.001 by ANOVA
Tumor Biol. (2014) 35:2211–2218 2215
release of cytochrome C which is combined with APAF-1,
triggering apoptosome activation [14]. It has been reported that
APAF-1 deficiency constitutes a significant mode of resistance
to cytochrome C-dependent apoptosis in human leukemia cells
[15]. Indeed, silencing of APAF-1 protein expression by hyper-
methylation of the gene promoter has been reported in several
human tumors, including malignant melanoma and acute leu-
kemia [16]. Silencing of APAF-1 expression in B cell chronic
lymphoblastic leukemia (B-CLL) constitutes a negative prog-
nostic marker in the case of concomitant p53 mutations [17]. In
addition, aberrant subcellular localization of the APAF-1
protein has been demonstrated in chemoresistant B lymphoma
cells, and resistance to etoposide was reversed upon APAF-1
overexpression [18]. In our study, we put emphasis on the role
of APAF-1 in iron overload MDS patients.
Iron overload-induced ROS generation may cause mito-
chondrial activation and cytochome C release, which gathers
APAF-1, triggering caspase-dependent apoptosis. The patho-
logical accumulation of iron aggravates oxidative stress and
mitochondrial damage, accelerating erythroid apoptosis. In
our study, agreed with APAF-1 expression, erythroid apopto-
sis rate in the IO group is higher than that in the non-IO group
(P <0.001). Meanwhile, paralleled with APAF-1 mRNA ex-
pression, caspase-9 activity in the IO group elevated much
more higher than that in the non-IO group, which suggested
that APAF-1 may be the key factor to erythroid apoptosis in
iron overload MDS.
Excess circulating iron is usually transformed into NTBI,
eventually transported to the cell cytoplasm and stored as
labile plasma iron (LPI) [3]. It had been proved that cells
incubated with FAC have an increased LPI level. Therefore,
we used FAC to set up an in vitro iron overloadmodel in K562
and MDS-L cell lines. It was found that incubation with
Fig. 5 The APAF-1 protein expression of the K562 cell line after
incubation of FAC in different concentrations. The figure shows APAF-
1 protein expression of the K562 cell line after different incubation of
FAC in different concentrations (from left to right: blank, 1 μmol/L,
2 μmol/L, 4 μmol/L, 8 μmol/L)





















































Fig. 6 The erythroid apoptosis
rate after incubation with FAC,
FAC+DFO, and silencingAPAF-1
in K562 and MDS-L cell lines.
The asterisk means that cell lines
were only treated with esiRNAs,
as blank control. To further
demonstrate the role of APAF-1 in
iron overload MDS, K562 and
MDS-L cell lines were incubated
with ferric ammonium citrate






small interfering RNAs (esiRNAs).
There is a significant decrease of
erythroid apoptosis rate between
FAC and FAC+DFO (P<0.001)
and FAC and FAC+esiRNAs
(P<0.001) in the K562 cell line.
There is also a significant decrease
of erythroid apoptosis rate between
FAC and FAC+DFO (P<0.001)
and FAC and FAC+esiRNAs
(P<0.001) in the MDS-L cell line
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different concentrations of FAC induced erythroid apoptosis
rate increase in K562 and MDS-L cell lines (P <0.001 and
P <0.001), and what is more, the apoptosis rates increased
with the increase of FAC concentrations, suggesting that
increased APAF-1 expression in iron overload elevates
erythroid apoptosis. In addition, Western blot analysis also
demonstrated that the protein expression of APAF-1 was
elevated along with increasing FAC concentration. Zermati
et al. suggested that APAF-1 deficiency contributes to
tumor progression not only by decreasing apoptotic caspase
activation but also by reducing the DNA damage-induced cell
cycle arrest, thus weakens the cytostatic effect of chemotherapy
or radiotherapy [19]. It seems that ineffective erythropoiesis in
iron overload may be caused by not only accelerated apoptosis
but also slowed down proliferation, which might be affected by
the increase of APAF-1 expression.
APAF-1 is transcriptionally and posttranslationally regulat-
ed during pathologic and physiologic conditions [20]. In order
to support our findings, a group of specific esiRNAs were
chosen for silencing of APAF-1 in K562 andMDS-L cell lines
to guarantee the specificity of RNA interference (RNAi).
After silencing of APAF-1 expression with specific esiRNAs,
the apoptosis rate and mRNA expression decreased markedly
in K562 (P <0.001 and P <0.001) and MDS-L (P <0.001 and
P <0.001) cell lines. This result supports that APAF-1 expres-
sion level does have a close contact with erythroid apoptosis.
Furthermore, after incubation with FAC+DFO, the apoptosis
rate and APAF-1 mRNA expression significantly declined
in K562 (P <0.001 and P <0.001) and MDS-L (P <0.001
and P <0.001) cell lines.When chelating the influence of iron,
both APAF-1 expression and erythroid apoptosis rate reduced,
indicating iron overload leading to an increase of erythroid
apoptosis through APAF-1. High expression of APAF-1 ele-
vates erythroid apoptosis in iron overload MDS.
Benites et al. demonstrated an increased APAF-1 expression
during erythroid differentiation of MDS progenitor cells.
Higher apoptotic rates could be a factor associated with the
increased expression of APAF-1 during erythroid differentia-
tion of CD34+ MDS cells [21]. Actually, some patients already
had iron overload before transfusion therapy was initiated due
to ineffective erythropoiesis [22]. Ineffective erythropoiesis
contributes to iron overload in MDS and is correlated with an
increase in intramedullary apoptosis of differentiated cells [23].
A large number of erythrocytes continue to differentiate but
cannot mature until they die of apoptosis, leading to the in-
crease of APAF-1 during erythroid differentiation progress.
Tanno et al. suggested that GDF15 measurements may be
helpful for predicting ineffective or apoptotic erythropoiesis
[24]. We performed a Pearson's correlation analysis to review
the association between GDF15 mRNA expression levels and
APAF-1 expression in the IO group and the non-IO group.
There was a statistical correlation of GDF15 with APAF-1 in
the non-IO group (r =0.542, P=0.025), but there was no
association between GDF15 and APAF-1 in the IO group
(r =0.170, P=0.499). In the non-IO patients, ineffective eryth-
ropoiesis might be the main cause of APAF-1 expression
increase. However, the influence of ineffective erythropoiesis
on APAF-1 expression in the IO group is weaker than that in
the non-IO group.
In conclusion, high expression of APAF-1 in iron overload
elevates erythroid apoptosis rate and may play an important
role during apoptosis process in MDS.
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